Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · IEX Real-Time Price · USD
45.81
-1.17 (-2.50%)
Jul 22, 2024, 9:41 AM EDT - Market open
Korro Bio Employees
As of December 31, 2023, Korro Bio had 102 total employees, including 101 full-time and 1 part-time employees.
Employees
102
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$795,941
Market Cap
422.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 102 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sonida Senior Living | 3,955 |
| Health Catalyst | 1,300 |
| Anika Therapeutics | 357 |
| Editas Medicine | 265 |
| Esperion Therapeutics | 240 |
| C4 Therapeutics | 145 |
| Kyverna Therapeutics | 96 |
| Aura Biosciences | 89 |
KRRO News
- 7 weeks ago - Korro to Participate in Upcoming June Investor and Scientific Conferences - GlobeNewsWire
- 2 months ago - Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference - GlobeNewsWire
- 2 months ago - Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Korro Announces $70 Million Private Placement - GlobeNewsWire
- 3 months ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 5 months ago - Korro to Present at the TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 6 months ago - Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio - GlobeNewsWire